SFSNX
Price
$22.32
Change
-$0.02 (-0.09%)
Updated
Jul 31 closing price
Net Assets
2.39B
VSCIX
Price
$141.38
Change
-$0.34 (-0.24%)
Updated
Jul 31 closing price
Net Assets
188.57B
Interact to see
Advertisement

SFSNX vs VSCIX

SFSNX vs VSCIX Comparison Chart in %
View a ticker or compare two or three
VS
SFSNX vs. VSCIX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SFSNX is a Hold and VSCIX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VSCIX has more cash in the bank: 189B vs. SFSNX (2.39B). VSCIX pays higher dividends than SFSNX: VSCIX (1.23) vs SFSNX (1.15). SFSNX was incepted earlier than VSCIX: SFSNX (19 years) vs VSCIX (29 years). SFSNX (0.25) is less costly to investors than VSCIX (0.03). SFSNX is a more actively managed with annual turnover of: 30.00 vs. VSCIX (17.00). SFSNX has a lower initial minimum investment than VSCIX: SFSNX (0) vs VSCIX (5000000). SFSNX annual gain was more profitable for investors over the last year : 28.78 vs. VSCIX (22.58). VSCIX return over 5 years is better than : 35.13 vs. SFSNX (26.87).
SFSNXVSCIXSFSNX / VSCIX
Total Expense Ratio0.250.03833%
Annual Report Gross Expense Ratio0.250.03833%
Fund Existence19 years29 years-
Gain YTD18.40814.591126%
Front LoadN/AN/A-
Min. Initial Investment05000000-
Min. Initial Investment IRAN/AN/A-
Net Assets2.39B189B1%
Annual Yield % from dividends1.151.2394%
Returns for 1 year28.7822.58127%
Returns for 3 years45.0243.44104%
Returns for 5 years26.8735.1376%
Returns for 10 years92.15156.0759%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSPKX20.050.12
+0.60%
Goldman Sachs US Eq Div and Prem Instl
GSIQX23.62N/A
N/A
Goldman Sachs GQG Ptnrs Intl Opps R
HSIIX29.59-0.08
-0.27%
Carillon Eagle Small Cap Growth I
CCWSX21.56-0.16
-0.74%
Baird Chautauqua International Gr Inv
RYCFX49.56-1.15
-2.27%
Rydex Biotechnology C